The stock of Aduro Biotech Incorporated (NASDAQ:ADRO) registered an increase of 4.37% in short interest. ADRO’s total short interest was 6.42 million shares in September as published by FINRA. Its up 4.37% from 6.15 million shares, reported previously. With 343,200 shares average volume, it will take short sellers 19 days to cover their ADRO’s short positions. The short interest to Aduro Biotech Incorporated’s float is 25.87%. About 156,004 shares traded hands. Aduro BioTech Inc (NASDAQ:ADRO) has risen 13.05% since February 8, 2016 and is uptrending. It has underperformed by 3.43% the S&P500.
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The company has a market cap of $896.11 million. The Firm is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. It currently has negative earnings. The Firm has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted , Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Out of 5 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. Aduro Biotech has been the topic of 6 analyst reports since October 20, 2015 according to StockzIntelligence Inc. FBR Capital maintained the stock on May 17 with “Outperform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.